Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.64 CAD
Change Today +0.01 / 1.59%
Volume 80.2K
As of 3:58 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

acasti pharma inc (APO) Snapshot

Open
C$0.62
Previous Close
C$0.63
Day High
C$0.68
Day Low
C$0.62
52 Week High
03/19/14 - C$1.49
52 Week Low
11/19/14 - C$0.41
Market Cap
68.1M
Average Volume 10 Days
60.1K
EPS TTM
C$-0.12
Shares Outstanding
106.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACASTI PHARMA INC (APO)

Related News

No related news articles were found.

acasti pharma inc (APO) Related Businessweek News

No Related Businessweek News Found

acasti pharma inc (APO) Details

Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

Founded in 2002

acasti pharma inc (APO) Top Compensated Officers

Chief Operating Officer
Total Annual Compensation: C$170.3K
Chief Global Strategic Officer
Total Annual Compensation: C$56.0K
Compensation as of Fiscal Year 2014.

acasti pharma inc (APO) Key Developments

Acasti Receives Full Data for Phase II TRIFECTA Trial

Acasti Pharma Inc. announced that it has received full data for its Phase II double blind, placebo controlled (TRIFECTA) trial. The full set of data further confirms and supports the positive Phase II TRIFECTA results announced in September 2014, on the safety and efficacy of CaPre in the treatment of patients with hypertriglyceridemia. As previously announced, the TRIFECTA trial's primary endpoint was met, with patients on 1 gram or 2 grams of CaPre achieving a statistically significant mean placebo-adjusted decrease in triglycerides from baseline. In addition, benefits in other key cholesterol markers were announced, including slight increases in HDL-C (good cholesterol), no deleterious effect on LDL-C (bad cholesterol) and no safety concerns. With full data, Acasti is now able to meet with the US Food and Drug Administration (FDA) to discuss next steps in the clinical development of CaPre.

Acasti Pharma Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine-Months Ended November 30, 2014

Acasti Pharma Inc. announced unaudited consolidated earnings results for the third quarter and nine-months ended November 30, 2014. For the quarter, revenues were $29,000 against $28,000 for the same period a year ago. Adjusted LBITDA was $2,099,000 against $1,574,000 a year ago. The year-over-year decrease in adjusted EBITDA was largely due to an increase in R&D expenses, resulting from higher professional fees and contract expenses related to Acasti's clinical trials. Net earnings were $3,012,000 against net loss of $3,856,000 a year ago, Loss was due to a decrease in the fair value of Acasti's derivative warrant liability arising from its 2013 public offering. Basic and diluted earnings per share were $0.03 against net loss per share of $0.05 a year ago. Book value per Class A share was $0.33 against $0.24 a year ago. Net cash used in operating activities was $2,230,129 against $865,021 a year ago. Acquisition of intangible assets was $19,337 against $51,312 a year ago. The decrease in the cash flows from operating activities is mainly attributable to the higher loss from operating activities after adjustments for non-cash items. Results from operating activities were $2,964,530 against $3,313,908 a year ago For the nine months, Revenue was $92,000 against $301,000 for the same period a year ago. Adjusted LBITDA was $6,244,000 against $4,607,000 a year ago. Net earnings were $656,000 against net loss of $9,059,000 a year ago. Basic and diluted earnings per share was $0.01 against net loss per share of $0.12 a year ago. Net cash used in operating activities was $4,575,276 against $2,081,207 a year ago. Acquisition of equipment was $34,650. Acquisition of intangible assets was $41,303 against $90,964 a year ago. The decrease in the cash flows from operating activities is mainly attributable to the higher loss from operating activities after adjustments for non-cash items, primarily offset by the changes in non-cash working capital items, primarily by a large decrease in trade and other receivables of $616 and a large increase in payable to parent corporation. Results from operating activities was $2,964,530 against $3,313,908 a year ago. Net cash used in operating activities was $4,575,276 against $2,081,207 a year ago. Acquisition of equipment was $34,650. Acquisition of intangible assets was $41,303 against $90,964 a year ago.

Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2014; Announces Resignation of Dr. Harlan W. Waksal, M.D. as Executive Vice-President, Business & Scientific Affairs

Acasti Pharma Inc. reported earnings results for the second quarter and six months ended August 31, 2014. For the quarter, the company reported revenues of $8,000 versus $266,000 for the quarter ended August 31, 2013. Adjusted EBITDA was negative of $2,449,000 versus negative of $1,763,000 in the prior year. Net loss was $3,712,000 versus a net loss of $3,238,000 in the prior year. The decrease in adjusted EBITDA was attributable to higher R&D expenses, along with increased general and administrative costs, largely associated with salaries and benefits. The higher net loss is due to the aforementioned factors along with a quarterly increase in the fair value of Acasti's derivative warrant liability arising from its 2013 public offering. For the six months, the company reported revenues of revenues of $64,000 versus $273,000 for the corresponding period ended August 31, 2013. Adjusted EBITDA was negative of $4,144,000 versus negative $3,033,000 in the prior year. Net loss was $2,356,000 versus a net loss of $5,203,000 in the prior year. The six-month year-over-year variances are mainly attributable to the factors listed above for the three-months ended August 31, 2014. As well, the lower net loss over the prior year is due to a year-to-date decrease in the fair value of Acasti's derivative warrant liability. The company also announced that Dr. Harlan W. Waksal, M.D. has stepped down as Executive Vice-President, Business & Scientific Affairs, following his recent appointment as President and CEO of Kadmon Corporation. He remains a Director on Acasti's Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APO:CN C$0.64 CAD +0.01

APO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzymotec Ltd $7.60 USD +0.19
View Industry Companies
 

Industry Analysis

APO

Industry Average

Valuation APO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 209.3x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 142.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACASTI PHARMA INC, please visit www.acastipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.